- Home
- NEGG vs CMPS Comparison
NEGG vs CMPS Comparison
Compare NEGG & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CMPS
- Stock Information
- Founded
- NEGG 2001
- CMPS 2020
- Country
- NEGG United States
- CMPS United Kingdom
- Employees
- NEGG N/A
- CMPS N/A
- Industry
- NEGG Other Specialty Stores
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- CMPS Health Care
- Exchange
- NEGG Nasdaq
- CMPS Nasdaq
- Market Cap
- NEGG 180.8M
- CMPS 280.2M
- IPO Year
- NEGG 2010
- CMPS 2020
- Fundamental
- Price
- NEGG $0.46
- CMPS $4.14
- Analyst Decision
- NEGG
- CMPS Strong Buy
- Analyst Count
- NEGG 0
- CMPS 6
- Target Price
- NEGG N/A
- CMPS $33.60
- AVG Volume (30 Days)
- NEGG 743.7K
- CMPS 663.3K
- Earning Date
- NEGG 01-07-2025
- CMPS 10-31-2024
- Dividend Yield
- NEGG N/A
- CMPS N/A
- EPS Growth
- NEGG N/A
- CMPS N/A
- EPS
- NEGG N/A
- CMPS N/A
- Revenue
- NEGG $1,391,833,000.00
- CMPS N/A
- Revenue This Year
- NEGG $6.01
- CMPS N/A
- Revenue Next Year
- NEGG N/A
- CMPS N/A
- P/E Ratio
- NEGG N/A
- CMPS N/A
- Revenue Growth
- NEGG N/A
- CMPS N/A
- 52 Week Low
- NEGG $0.43
- CMPS $3.86
- 52 Week High
- NEGG $1.45
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- NEGG 32.45
- CMPS 41.43
- Support Level
- NEGG $0.43
- CMPS $3.86
- Resistance Level
- NEGG $0.66
- CMPS $4.20
- Average True Range (ATR)
- NEGG 0.05
- CMPS 0.29
- MACD
- NEGG -0.01
- CMPS 0.02
- Stochastic Oscillator
- NEGG 13.43
- CMPS 27.01
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.